NeuroSense Therapeutics Ltd. (NRSN)
| Market Cap | 26.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.21M |
| Shares Out | 23.99M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,544 |
| Open | 1.080 |
| Previous Close | 1.044 |
| Day's Range | 1.050 - 1.120 |
| 52-Week Range | 0.512 - 1.500 |
| Beta | 1.34 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Jun 23, 2025 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under pr... [Read more]
Financial Performance
Financial StatementsNews
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. ...
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with ...
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass.
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Pha...
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass. , April 4, 2025 /PRNewswire/ -- NeuroSense ...
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
NEW YORK--(BUSINESS WIRE)---- $NRSN #ALS--PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation...
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on ...
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 PrimeC has already demonstrated a s...
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonst...
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
CAMBRIDGE, Mass. , Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense pla...
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE, Mass. , Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts...
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves s...
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CA...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
CAMBRIDGE, Mass. , Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved survi...
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
This cheap biotech offers investors a play on ALS if trial data continues to impress
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.